There is nothing inherently wrong with manufacturing Drug Substance at one site and filling Drug Product somewhere else.
The biopharma industry has worked this way for years.
Specialist providers can be excellent at what they do, and for some products the best combination may genuinely involve two different organizations.
But every additional provider creates an interface.
And interfaces are where surprisingly ordinary problems start consuming time.
For sponsors evaluating a fill finish CDMO, the question should therefore go beyond capacity and container format. It should include how well Drug Substance and Drug Product operations will connect.
Drug Substance does not simply arrive and get filled
Before aseptic filling begins, the receiving team needs to understand the material.
Concentration, formulation, storage conditions, shipping conditions, allowable hold time, filtration behaviour and temperature sensitivity all influence Drug Product execution.
Documentation must also move with the material.
Certificates, manufacturing records, release status, analytical data and shipping records need to arrive in the right form and at the right moment.
None of these tasks is unusual.
That is precisely the point.
A biologics program rarely loses weeks because one impossible scientific problem appears. It often loses them through a series of smaller dependencies that were never fully connected.
Every transfer needs a clear owner
When Drug Substance and Drug Product manufacturing sit with separate CDMOs, someone has to own the interface.
For example: Who confirms that the bulk is ready to ship? The shipping configuration must also be clearly defined. If an excursion occurs during transport, the responsible team needs to investigate it. Finally, someone must decide whether the receiving site can proceed when documentation is incomplete.
The sponsor frequently becomes the coordinator.
For large organizations with established CMC and supply teams, this may be perfectly manageable.
For smaller biotech companies, it can represent a substantial hidden workload.
Using an integrated biologics CDMO can reduce that coordination burden because both manufacturing stages operate within a shared project structure.
That does not eliminate technical work. It reduces the distance between the people who need to resolve it.
Fill finish requirements can influence Drug Substance earlier than expected
The relationship also works in the opposite direction.
Final presentation decisions can affect upstream planning.
If a protein must be filled at a specific concentration, Drug Substance manufacturing needs to deliver material within a suitable concentration and formulation range. If the product will be lyophilized, formulation and stability considerations may need to enter development well before filling.
Container choice, sterile filtration and available fill volumes can also influence the amount of bulk required.
This is why waiting until Drug Substance is finished before discussing aseptic fill and finish can be risky.
Drug Product is the next process, not a separate afterthought.
When do separate providers make sense?
Integration should not become a rule for its own sake.
A specialist Drug Product CDMO may offer a presentation, device, filling technology or commercial scale that the Drug Substance manufacturer does not support.
A sponsor may also have an established relationship with a preferred filling partner or need manufacturing redundancy across sites.
In those cases, using separate organizations can be the right decision.
The important thing is to recognize the additional transfer as a project in itself.
Responsibilities, samples, specifications, shipping, documentation, timelines and technical communication should all be planned before the bulk is ready.
The real advantage of integration is continuity
Keeping Drug Substance and fill finish connected does not automatically make a program better.
The advantage appears when integration preserves information and accelerates decisions.
A question about concentration can go directly to the manufacturing team. An analytical result can be discussed across DS and DP activities. A change in the manufacturing schedule can be reflected in the filling plan before it becomes a crisis.
Knowledge remains closer to the product.
At 53Biologics, GMP manufacturing, analytical support and aseptic fill finish are connected within one operating model, including liquid and lyophilized presentations. That allows clients to keep more of the route from biological production to final product within one team. The current 53Biologics fill and finish platform is designed specifically to connect bulk Drug Substance with final Drug Product operations.
Fewer handoffs where they add value
The right outsourcing model is not necessarily the one with the fewest suppliers.
It is the one in which every interface has a reason to exist.
If two specialist partners create the best technical route, build the program around that reality.
If there is no clear benefit to adding another transfer, integration may offer a simpler route with better continuity.
Before selecting your fill finish CDMO, ask one additional question:
What happens between the moment our Drug Substance is released and the moment the final Drug Product is ready?
That space between the two can matter more than it appears.
About 53Biologics:
53Biologics is the end-to-end biologics CDMO built to keep progress moving. We combine scientific expertise, integrated in-house capabilities and a close, hands-on way of working to help biotech teams make confident decisions, adapt as programs evolve and stay with one partner from early development through commercialization. With process development, manufacturing, analytics and fill-finish connected under one system, we reduce handoffs, protect continuity and help clients grow without disruption. We were made for this.
For more information or to speak with one of our experts email us at info@53biologics.com